Table 1.
Baseline patient and treatment characteristics.
Characteristic | Total Cohort (n = 278) | PCI Administered (n = 196)* | PCI Not Administered (n = 81)* | p-value |
---|---|---|---|---|
Median age (years, range) | 65.6 (38.7–90.6) | 64.2 (38.7–85.0) | 69.7 (44.9–90.6) | <0.001 |
Stage (n, %) | 0.58 | |||
I | 27 (11) | 21 (12) | 5 (7) | |
II | 28 (11) | 20 (11) | 8 (11) | |
III | 192 (78) | 135 (77) | 57 (81) | |
Unknown | 31 | 20 | 11 | |
ECOG status (n, %) | 1.00 | |||
0/1 | 235 (86) | 165 (86) | 69 (86) | |
2/3 | 38 (14) | 27 (14) | 11 (14) | |
Unknown | 5 | 4 | 1 | |
mCCI Score (n, %) | 0.40 | |||
0 | 176 (65) | 128 (67) | 47 (61) | |
1+ | 93 (35) | 63 (33) | 30 (39) | |
Unknown | 9 | 5 | 4 | |
Paraneoplastic Syndrome (n, %) | 0.20 | |||
No | 253 (93) | 181 (94) | 71 (90) | |
Yes | 19 (7) | 11 (6) | 8 (10) | |
Unknown | 6 | 4 | 2 | |
Pre treatment brain imaging (n, %) | 0.12 | |||
CT | 75 (28) | 52 (28) | 22 (27) | |
MRI | 174 (65) | 124 (67) | 50 (62) | |
None | 17 (6) | 8 (4) | 9 (11) | |
Unknown | 12 | 12 | 0 | |
Radiotherapy Dose | 0.43 | |||
40 Gy/15 | 183 (66) | 123 (63) | 59 (73) | |
45 Gy/30 BID | 82 (29) | 64 (33) | 18 (22) | |
60 Gy/30 | 3 (1) | 2 (1) | 1 (1) | |
66 Gy/33 | 3 (1) | 2 (1) | 1 (1) | |
Other | 7 (3) | 5 (3) | 2 (2) | |
Chemotherapy (n, %) | 0.29 | |||
Concurrent | 230 (83) | 158 (81) | 71 (88) | |
Sequential | 46 (17) | 36 (19) | 10 (12) | |
Unknown | 2 | 2 | 0 | |
Brain Surveillance (n, %) | 0.18 | |||
MRI | 155 (56) | 115 (59) | 40 (49) | |
No-MRI | 123 (44) | 81 (41) | 41 (51) | |
Brain Relapse Salvage Therapy (n, %)** | 1.00 | |||
WBRT | 58 (88) | 29 (88) | 29 (88) | |
SRS | 8 (12) | 4 (12) | 4 (12) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PCI, prophylactic cranial irradiation; mCCI, modified Charlson Comorbidity Index; WBRT, whole brain radiotherapy; SRS, stereotactic radiosurgery
PCI status unknown for one patient
Only patient with brain relapse and received salvage therapy were included